Question

In: Operations Management

Louis Vuitton is about to introduce a new item to its line of women’s shoes. What...

Louis Vuitton is about to introduce a new item to its line of women’s shoes. What three places can the unit sale for the new item come from that can affect the net impact on the company’s own margins?

The new Fresh-Cola product by Fresh-Cola Inc., a manufacturer of carbonated drinks, has just been introduced. What patterns develop during this phase of the product life cycle?

Solutions

Expert Solution

Louis Vuitton sales can be impacted if
1. There's a luxury brand in the market already having good brand image , who plans to diversify it's business into women footwear
2. Any competitive brand expanding it's business in those areas where Louis Vuitton planned to target
3. The existing shoes of the Louis Vuitton have built up the customer loyalty and thus the new product is unable to replace the earlier ones.
These three sources can negatively impact the sales revenue as well as the profit margin of the introduction of the new product in women's shoes category.

The phase that is discussed in the question is "INTRODUCTION PHASE" of the Product Life Cycle. During this phase the firm performs various tasks like developing the idea , testing of the market, market research , marketing the product and building its brand and quality. The patterns that are observed during this phase include building awareness through publicity, high costs with low profits, aggressive marketing, using price penetration ( high competition) or price skimming policy ( low competition) and product differentiation. Distribution is also through selective channels until consumers show positive response.


Related Solutions

Kolbe, product manager for a line of shoes, is wondering whether to introduce his product line...
Kolbe, product manager for a line of shoes, is wondering whether to introduce his product line into a new market area. A recent survey of a random sample of 500 households in that market showed a mean household income of $34,000 with a standard deviation of $2,000. On the basis of past experience and of comprehensive studies in current market areas, Kolbe believes the product line will be profitable only in markets where the mean household income (across all households)...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT